EA202092270A1 - APPLICATION OF ANTIBODY-DRUG CONJUGATES CONTAINING TUBULIN DESTROYING AGENTS FOR THE TREATMENT OF SOLID TUMOR - Google Patents

APPLICATION OF ANTIBODY-DRUG CONJUGATES CONTAINING TUBULIN DESTROYING AGENTS FOR THE TREATMENT OF SOLID TUMOR

Info

Publication number
EA202092270A1
EA202092270A1 EA202092270A EA202092270A EA202092270A1 EA 202092270 A1 EA202092270 A1 EA 202092270A1 EA 202092270 A EA202092270 A EA 202092270A EA 202092270 A EA202092270 A EA 202092270A EA 202092270 A1 EA202092270 A1 EA 202092270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
treatment
application
solid tumor
drug conjugates
Prior art date
Application number
EA202092270A
Other languages
Russian (ru)
Inventor
Энтони Тоа Као
Шира Джейн Гардай
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Priority claimed from PCT/US2019/023516 external-priority patent/WO2019183438A1/en
Publication of EA202092270A1 publication Critical patent/EA202092270A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение в целом относится к способам лечения солидных опухолей, включающим введение конъюгата лекарственное средство-линкер-антитело, где лекарственное средство представляет собой агент, разрушающий тубулин.The present invention generally relates to methods of treating solid tumors comprising administering a drug-linker-antibody conjugate, wherein the drug is a tubulin-degrading agent.

EA202092270A 2018-04-16 2019-03-22 APPLICATION OF ANTIBODY-DRUG CONJUGATES CONTAINING TUBULIN DESTROYING AGENTS FOR THE TREATMENT OF SOLID TUMOR EA202092270A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862658276P 2018-04-16 2018-04-16
PCT/US2019/023516 WO2019183438A1 (en) 2018-03-23 2019-03-22 Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor

Publications (1)

Publication Number Publication Date
EA202092270A1 true EA202092270A1 (en) 2021-02-03

Family

ID=74855491

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092270A EA202092270A1 (en) 2018-04-16 2019-03-22 APPLICATION OF ANTIBODY-DRUG CONJUGATES CONTAINING TUBULIN DESTROYING AGENTS FOR THE TREATMENT OF SOLID TUMOR

Country Status (1)

Country Link
EA (1) EA202092270A1 (en)

Similar Documents

Publication Publication Date Title
MX2023001685A (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
EA201890146A1 (en) METHODS OF TREATMENT OF SOLID TUMORS USING COMBINED THERAPY BY mTOR INHIBITOR IN THE FORM OF NANOPARTICLES
WO2018022668A3 (en) Neuromodulating compositions and related therapeutic methods for the treatment of cancer
EA201990643A1 (en) PHARMACEUTICAL COMPOUNDS
BR112019005247A2 (en) drug-resistant cancer therapy by administering anti-her2 antibody / drug conjugate
MX2018011627A (en) Prodrugs of cytotoxic active agents having enzymatically cleavable groups.
MX2020012997A (en) Splicing modulator antibody-drug conjugates and methods of use.
BR112015026297A2 (en) combination therapy consisting of a tor kinase inhibitor and a substituted 5-quinazolinone compound for cancer treatment
MX2020009842A (en) Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor.
EA202190403A1 (en) TREATMENT OF METASTATIC BRAIN TUMOR BY INJECTING AN ANTIBODY-DRUG CONJUGATE
EA202192122A1 (en) COMPOUNDS WITH FERROPTOSE-INDUCING ACTIVITY AND METHODS FOR THEIR APPLICATION
ZA201907225B (en) Treatment of her2 positive cancers
MX2019003694A (en) Methods of treating biliary tract cancer.
MX2018016332A (en) Combination chemotherapies.
EA201991985A1 (en) CONJUGATES ANTIBODY-MEDICINAL PRODUCT (KALS) BASED ON GDAC INHIBITORS AND USE IN THERAPY
EA201691570A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
MX2021005878A (en) Herboxidiene splicing modulator antibody-drug conjugates and methods of use.
EA201891968A1 (en) COMBINED TREATMENT USING LIV1-ADC AND CHEMOTHERAPEUTIC MEANS
EA202190457A1 (en) CONJUGATES FOR USE IN METHODS FOR TREATMENT OF CANCER
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
EA202090741A1 (en) CONJUGATES OF ANTIBODY TO TISSUE FACTOR AND DRUG AND THEIR APPLICATION IN TREATMENT OF CANCER
CL2020002637A1 (en) Cancer treatment methods.
BR112017028012A2 (en) THERAPY COMBINED WITH AN ANTIBODY-ANTI-HER2 DRUG CONJUGATE AND A BCL-2 INHIBITOR